Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PU-H71 + nab-paclitaxel
- Development stage
- Unknown
- Lead developer
- Memorial Sloan Kettering Cancer Center
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
PU-H71 + nab-paclitaxel is a combination therapy being investigated for cancer treatment, particularly in HER2-negative metastatic breast cancer. PU-H71 is an epichaperome inhibitor that binds to the ATP-binding site of HSP90, disrupting its chaperone activity and leading to degradation of client proteins involved in oncogenic signaling pathways. Nab-paclitaxel (Abraxane) is an albumin-bound formulation of paclitaxel that promotes assembly and stabilization of microtubules, inhibiting normal dynamic reorganization of the microtubule network essential for cell division. In clinical trials, this combination has shown evidence of clinical activity with more durable disease control observed in patients with high baseline epichaperome expression.
- Brand names
- Abraxane
- Other names
- PU-H71 + nanoparticle albumin-bound paclitaxelPU-H71 + Abraxane
02
Targets
TUBB (Tubulin (alpha and beta subunits))HSP90 (Heat shock protein 90 chaperone complex)
Beyond the preview
Go deeper on PU-H71 + nab-paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PU-H71 + nab-paclitaxel.